Navigation Links
MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs
Date:1/13/2009

    MEMOTEXT(R) Personalized Adherence Interventions Incorporated into
    First-of-its-Kind Study Funded by Microsoft HealthVault Be Well Fund

BETHESDA, MD, Jan. 13 /PRNewswire/ - MEMOTEXT announced today that Johns Hopkins University's Wilmer Eye Institute will conduct a clinical trial on patient adherence and clinical outcomes for people with glaucoma using technology developed by MEMOTEXT. The clinical trial, titled "The Impact of Automated Dosing Reminders on Medication Adherence Using HealthVault," is funded by a Microsoft(R) HealthVault(TM) Be Well Fund grant. The 14-month study, to be led by Michael V. Boland, M.D., Ph.D. of the Wilmer Eye Institute, will recruit 500 patients and use telephone calls and text messages in an effort to improve patient outcomes by improving medication adherence.

"We believe this new interface will significantly improve medication adherence in patients with glaucoma," says Amos Adler, President of MEMOTEXT. "It is an honor to collaborate on this special grant, and we are confident this trial will demonstrate that MEMOTEXT's technology-driven adherence solutions can make a significant difference in the lives of patients managing various conditions."

Studies have shown that medication non-adherence costs North America more than $100 billion and 125,000 lives every year. Medication non-adherence impacts all levels of health management, including treatment effectiveness and unnecessary hospitalizations, and almost six percent of all hospital admissions are due to failed patient adherence. Research also indicates that 70% of prescriptions are never consumed and 20% of all new drug prescriptions are never filled for the first time - with adherence rates as low as 10-20% for some disease states.

Approximately 40% of glaucoma patients have difficulty taking their eye drops on a regular basis, resulting in poor care despite an appropriate physician diagnosis and treatment
'/>"/>

SOURCE MEMOTEXT Personalized Adherence Solutions
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Pennsylvania Patient Safety Authority Launches New Website and Design With New Tagline Analyzing, Educating and Collaborating for Patient Safety
2. Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
3. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
4. Johnson & Johnson Announces Receipt of Israeli Antitrust Approval for Acquisition of Omrix
5. YMCA of the USA Expands Healthy Communities Initiatives With $6.8 Million Grant from the Robert Wood Johnson Foundation
6. Johnson Matthey Medical Announces Expansion
7. Posit Science Invited to Speak at Johns Hopkins University About Cutting Edge Cognitive Training Interventions
8. Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity
9. Video: Magic Johnson Foundation and Abbott Call for Greater Prevention, Testing and Treatment on World AIDS Day
10. Johns Hopkins and Makerere University to collaborate on African health education initiative
11. Johnson & Johnson Begins Tender Offer to Acquire Omrix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... of research at the University of Utah,s John A. ... Society of Eye Research (ISER) as the recipient of ... International Award in Retina Research., The award recognizes lifetime ... significant contribution to the understanding of vitreoretinal diseases or ... the ISER Biennial Meeting in San Francisco, where Marc ...
(Date:7/22/2014)... comes to heart disease, Dr. Ross Feldman says women are ... disease was a men,s-only disease, however, data has shown that ... heart disease and are less likely to be adequately diagnosed ... week in the British Journal of Clinical Pharmacology ... women and helps to identify which women are more prone ...
(Date:7/22/2014)... 22, 2014) -- The American Society of Hematology (ASH) ... H. Coulter Award for Lifetime Achievement in Hematology, to ... Island Jewish (LIJ) School of Medicine for his 50-year ... education and mentoring, and exceptional patient care. , ... Hematology is bestowed on an individual who has been ...
(Date:7/22/2014)... 2014 Legislation backed by the ... Local Pharmacies Act of 2014”) championing so-called “any ... undermine the availability of lower cost preferred pharmacy ... over the next 10 years, according to new ... Pharmaceutical Care Management Association (PCMA). , The drugstore ...
(Date:7/22/2014)... As reported on July 17, 2014 by ABC ... her favorite beauty products, “ Botox , that’s pretty much ... Botox has changed my life” by halving the amount ... her various, daily appearances. “Suddenly my eyelids are no ... , “I think that Kelly Ripa’s response to the question ...
Breaking Medicine News(10 mins):Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:Gene variant identified as a heart disease risk factor for women 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2
... multispecialty medical group in Southern California, announced the opening of its ... Monrovia. , ... Torrance, CA (PRWEB) December 16, 2008 ... Southern California, announced the opening of its newest medical office ...
... portal that features the latest news, facts and nutritional updates about ... acai plant and the acai berry fruit to help the general ... ... Dallas, TX (PRWEB) December 16, 2008 -- The announcement ...
... Inc.(CTI),(Nasdaq and MTA: CTIC) announced today they have ... a 50/50 owned joint venture, RIT,Oncology LLC (LLC), ... United States. In connection with the closing, ... and will receive an,additional $7.5 million in early ...
... Dec. 15 Today, the U.S. Food,and Drug Administration ... along with diet to help lower triglycerides,and LDL cholesterol, ... TRILIPIX is the first and only fibrate to ... In certain patients, treatment guidelines,recommend the combination of a ...
... Calif.) -- A secondary analysis of a large, multicenter ... fruits, vegetables and fiber and somewhat lower in fat ... of recurrence in a subgroup of early-stage breast cancer ... by approximately 31 percent. These patients typically have higher ...
... say , , MONDAY, Dec. 15 (HealthDay News) -- Men ... spread beyond the wall of the prostate gland -- ... risk of dying in half, a new study has ... much longer, the Swedish research team concluded. In fact, ...
Cached Medicine News:Health News:HealthCare Partners Opens a New Medical Office in Monrovia, CA 2Health News:AcaiBerryMD.com Explains the Real Facts About the Acai Berry Fruit 2Health News:AcaiBerryMD.com Explains the Real Facts About the Acai Berry Fruit 3Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 2Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 3Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 4Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 5Health News:(Multimedia Version): Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 2Health News:(Multimedia Version): Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 3Health News:(Multimedia Version): Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 4Health News:Diet may cut risk of breast cancer recurrence in women without hot flashes 2Health News:Diet may cut risk of breast cancer recurrence in women without hot flashes 3Health News:Radiation Plus Hormone Therapy Cuts Prostate Cancer Deaths 2Health News:Radiation Plus Hormone Therapy Cuts Prostate Cancer Deaths 3
(Date:7/22/2014)... -- Research and Markets has announced the ... by Reagent, by Application - Global Forecast to 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Biopharmaceuticals are pharmaceutical products ... the most important and widely used techniques for biopharmaceutical ... the cell culture market in 2013. Growth in the ...
(Date:7/22/2014)... , July 22, 2014  Decision Resources Group finds that ... Canada will remain relatively stagnant at a value ... fact that percutaneous coronary intervention (PCI) volumes are growing faster ... markets, such as the United States ... largely driven by the increase in penetration of PCI procedures ...
(Date:7/22/2014)... , July 22, 2014 Legislation backed ... Access to Local Pharmacies Act of 2014") championing ... D would undermine the availability of lower cost ... $21 billion over the next 10 years, according ... by the Pharmaceutical Care Management Association (PCMA). ...
Breaking Medicine Technology:Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3New Study: H.R. 4577 to Cost $21 Billion over 10 Years 2New Study: H.R. 4577 to Cost $21 Billion over 10 Years 3
... The AlphaPette Pipettor is the #1 ... Offers accuracy, comfort, and reliability. Continuously ... volume readout sub-micrometer. Easy interchangeable ejector ... tiny hands. Adjustable rapid pipet tip ...
... The Finnpipette Digital offers improved ergonomics ... rounded handle, modified grippy finger rest ... operator comfort and efficiency. Finnpipette Digitals ... power-boosted gearing mechanism (pat. pend.) and ...
... is the #1 Pipettor for sub-microliter ... and reliability. Continuously adjustable. Features lPLUS, ... Easy interchangeable ejector buttons to fit ... rapid pipet tip ejector with three ...
... Recommended for aqueous samples of moderate viscosity and density. Proven ergonomic design ... Volume Range(ul) ... 0.8~1.5 Imprecision(%) ... (ul) ...
Medicine Products: